🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with estimates suggesting more than 82 million infections per year. Particularly high rates are seen in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in close succession. This drug, which is also used to treat UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone represents a major breakthrough in the management of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per data detailed in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which uses a dual-drug approach. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced hope. Access to a easy-to-administer therapy of this kind is described as a "game-changer" for managing the epidemic. This is considered essential to reduce the burden of the infection for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.